Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
plasmid DNA HIV-1 vaccine
- Development stage
- Phase 2
- Lead developer
- Swedish Institute for Infectious Disease Control
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular, Intradermal
01
Overview
The plasmid DNA HIV-1 vaccine (specifically developed as HIVIS-DNA) is an investigational multigene, multiclade DNA-based vaccine candidate designed to prevent HIV-1 infection. Developed under the HIV Vaccine Immunogenicity Study (HIVIS) program by the Swedish Institute for Infectious Disease Control (SMI) in collaboration with the Karolinska Institutet and Tanzanian partners, the vaccine consists of plasmids encoding HIV-1 genes env (subtypes A, B, C), rev (subtype B), gag (subtypes A, B), and RT (subtype B). It is typically evaluated as a priming agent in a heterologous prime-boost regimen, followed by a boost with the recombinant Modified Vaccinia Ankara (MVA-CMDR) vaccine. The vaccine aims to elicit broad cellular and humoral immune responses against multiple HIV-1 clades.
- Other names
- HIVIS-DNA vaccineHIVIS DNA vaccineHIVIS-03 DNA vaccineHIVIS03 DNA vaccineHIVIS 03 DNA vaccine
02
Targets
Env (HIV-1 envelope glycoprotein)Rev (HIV-1 Rev)Human immunodeficiency virus type 1 reverse transcriptaseGag (HIV-1 Gag polyprotein)gp41 (Human immunodeficiency virus type 1 glycoprotein 41)
Beyond the preview
Go deeper on plasmid DNA HIV-1 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on plasmid DNA HIV-1 vaccine.